Free tracked shipping
LYZE LABS

Comparisons

Trevogrumab vs Garetosmab vs Bimagrumab vs Apitegromab: The 2026 Myostatin Inhibitor Comparison

Four antibodies, one muscle pathway, four different points of attack. What trevogrumab, garetosmab, bimagrumab and apitegromab each block, what the trials showed, and how to choose between them.

Lyze Labs Research Team · Updated · 13 min read

In this guide

Trevogrumab and garetosmab are two different antibodies from the same Regeneron program, and they block two different signals. Trevogrumab (REGN1033) blocks myostatin, also called GDF-8. Garetosmab (REGN2477) blocks activin A. Myostatin and activin A are the two main brakes on muscle size, and both act through the same receptors, which is why the two antibodies are studied together.

The two most common questions have short answers. What is the difference? Trevogrumab binds myostatin and leaves GDF11 alone. Garetosmab binds activin A, AB and AC and leaves activin B, inhibin A, the BMPs, myostatin and GDF11 alone. Why are they searched together? Regeneron tests them together in the Phase 2 COURAGE obesity trial, where semaglutide plus trevogrumab plus garetosmab gave the best body-composition result and the worst tolerability, in the same group.

Bimagrumab and apitegromab work on the same pathway at different points. By late 2026, two of the four had FDA approval for rare diseases, and all four are still studied for muscle. This guide compares them on how they work, on the published trial numbers, and on what each one is good for as a research tool.

Key Takeaways

  • Trevogrumab traps myostatin in its mature, latent and pro-forms, with no GDF11 cross-reactivity. Use it when an effect must be traced to myostatin alone.
  • Garetosmab traps activin A, AB and AC, and nothing else in its protein family. Use it to separate activin signals from BMP signals in the same tissue. It is now an approved medicine for a rare bone disease (Pasatru, August 2026).
  • Bimagrumab blocks the receptors (ActRIIA and ActRIIB) instead of a signal, so it stops myostatin and activin A together. Biggest effect, but you cannot tell which signal did the work.
  • Apitegromab binds only the inactive pro- and latent forms of myostatin. The narrowest target of the four. It is now approved for spinal muscular atrophy (Isembyld, September 2026).
  • In COURAGE, people on semaglutide alone lost 6.5% of their lean body mass at 26 weeks. Adding trevogrumab cut that to 3.3%. Adding garetosmab as well cut it to 2.0%.
  • In BELIEVE, bimagrumab at 30 mg/kg raised lean mass by 2.5%, while semaglutide 2.4 mg alone lowered it by 7.4%.
  • None of these are peptides. All four are ~145 kDa antibodies grown in mammalian cell culture, and a peptide Certificate of Analysis cannot characterise any of them.

The Comparison, at a Glance

PropertyTrevogrumabGaretosmabBimagrumabApitegromab
CodeREGN1033REGN2477BYM338SRK-015
DeveloperRegeneronRegeneronEli LillyScholar Rock
TargetMyostatin (GDF-8)Activin A, AB, ACActRIIA / ActRIIBPro- and latent myostatin
Level of actionLigandLigandReceptorLigand precursor
IsotypeHuman IgG4-kappaHuman IgG4Human IgG1Human IgG4
Does not bindGDF11Activin B, inhibin A, BMP-2/6/9/10, GDF8, GDF11(blocks the receptor, so ligand-agnostic)Mature myostatin
Key trialCOURAGECOURAGE, OPTIMA (FOP)BELIEVESAPPHIRE, EMBRAZE
FDA status (Oct 2026)InvestigationalApproved for FOP (Pasatru)InvestigationalApproved for SMA (Isembyld)
CAS1429201-24-02097125-54-51015346-48-71943322-31-9

The most useful row in that table is the level of action. Everything else follows from it.

Ligand Trap vs Receptor Blocker: Why It Decides Your Experiment

Myostatin, activin A, activin B, GDF11 and several BMPs all send their signal through a small shared set of receptors, which feed the same SMAD2 and SMAD3 machinery inside the cell. That crowding is the central problem in this field.

A receptor blocker like bimagrumab sits on ActRIIA and ActRIIB and stops everything that signals through them. The effect is the largest available, because several brakes come off at once. The cost: no test downstream can tell you which signal mattered.

A ligand trap like trevogrumab, garetosmab or apitegromab catches one signal outside the cell and leaves the receptor free for everything else. The effect is smaller, and you know where it came from.

This is why the older decoy receptors (soluble ActRIIB-Fc) produce striking results and unclear papers. They catch myostatin, GDF11, activin A and several BMPs at once. If your study needs to say this signal did this, a decoy receptor cannot get you there, and a selective antibody can.

Trevogrumab (REGN1033)

A fully human IgG4-kappa antibody against myostatin. CAS 1429201-24-0, molecular formula C6374H9884N1696O2018S46, 144,037.80 g/mol.

It binds the mature, latent and pro-forms of myostatin, and it does not cross-react with GDF11, even though the active parts of the two proteins are about 90 percent identical. That selectivity is the property worth paying for: GDF11 and myostatin are the pair most tools in this field cannot tell apart. In monkeys, Regeneron's team used the two antibodies to show that activin A matters more for primate muscle mass than myostatin does (Latres, 2017).

The IgG4 backbone is a deliberate choice. IgG4 barely triggers the immune system's attack functions, so an antibody that soaks up a free-floating signal does not also mark the cells that carry it for destruction.

See the Trevogrumab research guide and specifications.

Garetosmab (REGN2477)

A fully human IgG4 antibody against activin A. CAS 2097125-54-5, about 145.5 kDa.

Its selectivity list is long and clean. It binds the activins built on the inhibin beta-A subunit: activin A, activin AB and activin AC. It does not bind or block activin B, inhibin A, BMP-2, BMP-6, BMP-9, BMP-10, GDF8 or GDF11.

Its other research setting is bone. Regeneron scientists found that activin A drives the extra bone growth (heterotopic ossification) in fibrodysplasia ossificans progressiva (FOP), a rare disease where a faulty ACVR1 receptor misreads activin A as a signal to make bone. In healthy tissue activin A does not drive bone formation.

After a Phase 2 trial (Di Rocco, 2023), the Phase 3 OPTIMA trial in 63 adults with FOP found that garetosmab cut new bone lesions by 94% at 3 mg/kg and 90% at 10 mg/kg against placebo over 56 weeks. The FDA approved it on 19 August 2026 as Pasatru, for adults with FOP.

See the Garetosmab research guide and specifications.

What COURAGE Actually Showed

COURAGE (NCT06299098) is Regeneron's Phase 2 obesity study combining semaglutide with trevogrumab, with or without garetosmab. The full 26-week results were presented at the EASD 2025 meeting.

First, the trial measured the problem it exists to solve: about one third of the weight lost on semaglutide alone was lean mass, not fat.

Change in lean body mass from baseline at 26 weeks:

ArmLean body mass change
Semaglutide alone-6.5%
Semaglutide + trevogrumab 200 mg-3.3%
Semaglutide + trevogrumab 400 mg-3.8%
Semaglutide + trevogrumab + garetosmab-2.0%

The triplet reached 80.9 percent lean mass preservation and a 27.3 percent increase in fat mass reduction versus semaglutide alone.

The other half of the result matters just as much. Semaglutide plus trevogrumab was generally well tolerated, but the triplet had a much higher rate of people stopping treatment because of side effects and other adverse events. Adverse events seen in at least 5 percent of any group included muscle spasms, nausea, constipation, fatigue, diarrhea, headache, vomiting, acid reflux, upper respiratory infections, nasopharyngitis, urinary tract infections, influenza and COVID-19.

The best body composition and the most dropouts came from the same group. That is the key fact about adding activin A blockade on top of myostatin blockade, and it is why the two antibodies are studied as a pair rather than assumed to work better together.

Bimagrumab (BYM338)

Bimagrumab is the outlier: a human IgG1 antibody that blocks the activin type II receptors themselves rather than any single signal. Myostatin and activin A both act through ActRIIA and ActRIIB, so blocking the receptor stops both at once.

An earlier Phase 2 trial in 75 adults with type 2 diabetes and obesity set the pattern. Over 48 weeks, fat mass fell 20.5% on bimagrumab against 0.5% on placebo, while lean mass rose 3.6% against a 0.8% drop (Heymsfield, 2021).

The BELIEVE Phase 2b trial (NCT05616013) randomized 507 adults with obesity across nine groups. At week 48, body weight fell by 9.3 kg on bimagrumab 30 mg/kg, 14.2 kg on semaglutide 2.4 mg and 17.8 kg on the two combined, against 3.3 kg on placebo (Heymsfield, 2026). Body composition at week 72, as presented at ADA 2025:

Measure at week 72Semaglutide 2.4 mgBimagrumab 30 mg/kgCombination
Lean mass-7.4%+2.5%preserved
Total body fat mass-27.8%-28.5%-45.7%
Visceral adipose tissue-35.8%n/r-58.2%

The combination cut body weight by about 22 percent, with 92 percent of the loss coming from fat.

Bimagrumab adding lean mass where semaglutide removed it is the strongest body-composition signal any of the four has produced. The trade-off is the one above: blocking the receptor cannot tell you which signal did the work.

Apitegromab (SRK-015)

Apitegromab takes the narrowest approach of the four. It binds the pro- and latent forms of myostatin, the inactive precursors, and does not bind active myostatin at all. Blocking activation, rather than the active protein, gives it the tightest specificity in its protein family, and has been proposed as the reason it is well tolerated.

It is also the furthest along. In the Phase 3 SAPPHIRE trial in spinal muscular atrophy (188 patients), treated children aged 2 to 12 scored 1.8 points higher than placebo on the Hammersmith motor scale at 12 months (Crawford, 2025). It was the first muscle-targeted drug to succeed in a Phase 3 SMA trial, and the FDA approved it on 11 September 2026 as Isembyld, for patients aged 2 and older who already take an SMN2-targeted treatment.

In obesity, the EMBRAZE Phase 2 trial paired apitegromab 10 mg/kg with tirzepatide over 24 weeks and reported 1.9 kg less lean mass loss than placebo (P=0.001) at similar total weight loss, a 54.9 percent retention of lean mass relative to placebo.

How to Choose Between Them

If your design needsReach for
An effect traced to myostatin and not GDF11Trevogrumab
Activin A separated from BMP signals in the same tissueGaretosmab
The biggest body-composition effect, source not requiredBimagrumab
Myostatin activation blocked without touching the active proteinApitegromab
Both main ActRII signals measured in one modelTrevogrumab + Garetosmab, run alone and together

The last row is the design COURAGE used, and it is why these two are ordered as a pair. Neither antibody touches the other's target, so the combination adds up cleanly instead of muddying the result, which a receptor blocker cannot give you.

None of These Are Peptides, and the COA Proves It

Several research-chemical vendors list trevogrumab and garetosmab under "peptides", some literally titled "trevogrumab peptide vial". That label is wrong, and it has practical consequences.

A peptide like BPC-157 is a short chain built by chemical synthesis. These four are ~145 kDa antibodies: four protein chains held together by disulfide bonds and carrying sugar groups, grown in Chinese hamster ovary cells and purified on Protein A columns. Peptide synthesis cannot make them at any scale.

That changes the certificate entirely:

AttributePeptide COAAntibody COA
PurityRP-HPLC area percentSEC-HPLC monomer content
IdentityESI-MS charge stateDeglycosylated intact mass + SDS-PAGE
Chain integrityn/aSDS-PAGE, reduced and non-reduced
WaterKarl Fischer titrationnot applicable
Activityn/aTarget binding by ELISA
Selectivityn/aCounter-screen against lookalike ligands

Reversed-phase conditions denature an antibody, so an RP-HPLC purity number for one is meaningless. A single mass-spec reading means little for a protein whose sugar groups vary from molecule to molecule. And the property you are actually buying, selectivity, appears on neither.

If a supplier hands you an RP-HPLC trace and a Karl Fischer water content for a monoclonal antibody, that certificate was written for a different kind of molecule. Our guide to verifying purity and COAs covers the peptide side of this in detail.

Frequently Asked Questions

What is the difference between trevogrumab and garetosmab?

They block different signals in the same pathway. Trevogrumab (REGN1033) binds myostatin, also called GDF-8, in its mature, latent and pro-forms, and does not cross-react with GDF11. Garetosmab (REGN2477) binds activin A, activin AB and activin AC, and does not bind activin B, inhibin A, BMP-2, BMP-6, BMP-9, BMP-10, GDF8 or GDF11. Both are fully human IgG4 antibodies from Regeneron, and both trap a signal rather than block a receptor.

Why are trevogrumab and garetosmab searched together?

Because Regeneron studies them together. In the Phase 2 COURAGE obesity trial (NCT06299098), semaglutide was combined with trevogrumab, with or without garetosmab. Myostatin and activin A are the two main brakes on muscle mass and act through the same receptors, so blocking one leaves the other working. The triplet gave the best body composition in the study and also the highest rate of people stopping treatment.

Is trevogrumab better than bimagrumab?

They do different jobs. Bimagrumab blocks the ActRIIA and ActRIIB receptors, so it stops myostatin and activin A together and has the bigger effect: in BELIEVE it raised lean mass by 2.5 percent where semaglutide alone lowered it by 7.4 percent. Trevogrumab traps only myostatin, so its effect is smaller but can be traced to one signal. Choose the receptor blocker for the biggest effect and the ligand trap for a clean answer.

What makes apitegromab different from trevogrumab?

Apitegromab binds only the pro- and latent precursor forms of myostatin and ignores the active protein, so it blocks activation rather than the active signal. Trevogrumab binds mature, latent and pro-forms alike. Apitegromab has the narrowest target of the four, and it is the furthest along: the FDA approved it for spinal muscular atrophy on 11 September 2026 as Isembyld.

Are trevogrumab and garetosmab peptides?

No, and vendors listing them as peptides are mislabelling them. Both are monoclonal antibodies of roughly 145 kDa, built from two heavy chains and two light chains joined by disulfide bonds and carrying sugar groups, made by recombinant expression in CHO mammalian cell culture. Peptide synthesis cannot make a molecule of that size or shape. The distinction determines how the material is tested, stored and handled.

Are any of these approved medicines?

Two are. Garetosmab was approved by the FDA on 19 August 2026 as Pasatru, for adults with fibrodysplasia ossificans progressiva, and apitegromab on 11 September 2026 as Isembyld, for spinal muscular atrophy. Trevogrumab and bimagrumab are still investigational. Material supplied for research is a reagent, unrelated to any clinical supply chain, and is not for human use.

What is the COURAGE trial?

COURAGE (NCT06299098) is Regeneron's Phase 2 study testing whether adding trevogrumab, with or without garetosmab, to semaglutide preserves lean mass during weight loss in adults with obesity. Results presented at EASD 2025 showed lean body mass change at 26 weeks of -6.5% for semaglutide alone, -3.3% adding trevogrumab 200 mg, -3.8% adding trevogrumab 400 mg, and -2.0% for the triplet, with the triplet reaching 80.9% lean mass preservation and 27.3% greater fat mass reduction.

Specifications and Certificates

Both Regeneron antibodies are stocked as research reference standards with batch-matched antibody Certificates of Analysis covering SEC-HPLC monomer purity, SDS-PAGE identity and chain integrity, deglycosylated intact mass, ELISA binding activity and the selectivity counter-screen. Full specifications, pricing per vial and the published certificates are on the Trevogrumab and Garetosmab product pages, and every published certificate is listed at lab results.

Studies Cited

This guide is for education. It is not medical advice. Every compound we supply is for laboratory research only and is not for human use.

Kits in this guide

Questions about a compound?

A person answers on WhatsApp, even at 3 a.m. your time.

Ask on WhatsApp